MedMira Completes Acquisition of BAG-1 Technology
MedMira Inc. announced that it has closed the transaction to acquire the BAG-1, an emerging cancer marker technology, that was announced on April 3, 2006. Under the terms of the acquisition agreement MedMira will acquire the BAG-1 technology for a purchase price of $600,000. The purchase price will be paid in installments as milestones in the commercialization of this technology, as specified in the agreement are achieved. The purchase price will be paid through the issuance of common shares at the closing market price of MedMira common shares the business day immediately preceding the date the milestone is achieved, with a minimum issue price of $0.476.
In accordance with the terms of the agreement, MedMira has issued 89,286 common shares to Dr. Shou-Ching Tang, the developer of the technology and a member of the MedMira Board of Directors, at an issue price of $0.56. The maximum number of shares that will be issued under this agreement is 1,244,748 common shares. The shares issued will be subject to a 4 month hold period.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.